A carregar...
Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
BACKGROUND: Dolutegravir (DTG) is a once-daily unboosted second-generation integrase-inhibitor that along with two nucleoside reverse transcriptase inhibitors is one of several regimens recommended by the United States, United Kingdom and European Union for first-line antiretroviral treatment of peo...
Na minha lista:
| Publicado no: | PLoS One |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Public Library of Science
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5063380/ https://ncbi.nlm.nih.gov/pubmed/27736859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0162775 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|